Programmed death-ligand 1 (PD-L1) expression is a predictor of immune checkpoint
inhibitor (ICI) treatment e cacy. The clinical e cacy of ICIs for non-small-cell lung cancer (NSCLC)
patients harboring major mutations, such as EGFR or ALK mutations, is limited. We genotyped
190 patients with advanced lung adenocarcinomas who received nivolumab or pembrolizumab
monotherapy, and examined the e cacy in NSCLC patients with or without major mutations.
Among the patients enrolled in the genotyping study, 47 patients harbored EGFR mutations, 25 patients
had KRAS mutations, 5 patients had a HER2 mutation, 6 patients had a BRAF mutation, and 7 patients
had ALK rearrangement. The status of PD-L1 expression was evaluated in 151 patients, and the
rate of high PD-L1 expression ( 50%) was significantly higher in patients with ALK mutations.
The progression-free survival was 0.6 (95% CI: 0.2–2.1) months for ALK-positive patients and 1.8 (95%
CI: 1.2–2.1) months for EGFR-positive patients. All patients..... READ ARTICLE
International Journal of Molecular Sciences DOI:10.3390/ijms21072623
Authors: Yuko Oya, Hiroaki Kuroda, Takeo Nakada, Yusuke Takahashi, Noriaki Sakakura, Toyoaki Hida
